KEGG   NETWORK: N01316
Entry
N01316                      Network                                

Name
SARS-CoV-2 S/N to lectin pathway of coagulation activation
Definition
(S,N) -> (MBL2+MASP1/2) -> F2 -- FG -> Fibrin
  Expanded
(K24152,K24106) -> (4153+(5648,10747)) -> 2147 -- (2243+2244+2266) -> C00290
Class
nt06136 Complement activation (viruses)
nt06171 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Type
Variant
Pathway
hsa05171  Coronavirus disease - COVID-19
Disease
H02398  COVID-19
Gene
4153  MBL2; mannose binding lectin 2
5648  MASP1; mannan binding lectin serine peptidase 1
10747  MASP2; mannan binding lectin serine peptidase 2
2147  F2; coagulation factor II, thrombin
2243  FGA; fibrinogen alpha chain
2244  FGB; fibrinogen beta chain
2266  FGG; fibrinogen gamma chain
Perturbant
K24152 (S)  S; SARS coronavirus spike glycoprotein
K24106 (N)  N; SARS coronavirus nucleocapsid protein
Metabolite
C00290  Fibrin
Reference
  Authors
Lo MW, Kemper C, Woodruff TM
  Title
COVID-19: Complement, Coagulation, and Collateral Damage.
  Journal
J Immunol 205:1488-1495 (2020)
DOI:10.4049/jimmunol.2000644
Reference
  Authors
Jodele S, Kohl J
  Title
Tackling COVID-19 infection through complement-targeted immunotherapy.
  Journal
Br J Pharmacol (2020)
DOI:10.1111/bph.15187
Reference
  Authors
Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S
  Title
Rationale for targeting complement in COVID-19.
  Journal
EMBO Mol Med 12:e12642 (2020)
DOI:10.15252/emmm.202012642
LinkDB

DBGET integrated database retrieval system